Clofazimine for the treatment of tuberculosis
Shorter (6-9 months), fully oral regimens containing new and repurposed drugs are now the first-choice option for the treatment of drug-resistant tuberculosis (DR-TB). Clofazimine, long used in the treatment of leprosy, is one such repurposed drug that has become a cornerstone of DR-TB treatment and...
Saved in:
Main Authors: | Jacob A. M. Stadler (Author), Gary Maartens (Author), Graeme Meintjes (Author), Sean Wasserman (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2023-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Dolutegravir for second-line treatment: Programmatic implications of new evidence
by: Ying Zhao, et al.
Published: (2022) -
Case report: Emergence of dolutegravir resistance in a patient on second-line antiretroviral therapy
by: Kairoonisha Mahomed, et al.
Published: (2020) -
Virologic outcomes with tenofovir-lamivudine-dolutegravir in adults failing PI-based second-line ART
by: Ying Zhao, et al.
Published: (2024) -
The risks of concurrent treatment with tenofovir and aminoglycosides in patients with HIV-associated tuberculosis
by: Chris Kenyon, et al.
Published: (2011) -
Alere Determine-tuberculosis lipoarabinomannan positivity in disseminated non-tuberculous mycobacteria: An illustrative case series
by: Riana Greyling, et al.
Published: (2022)